Inflectra® (infliximab-dyyb) – Expanded indication
June 18, 2019 - The FDA approved Celltrion/Pfizer’s Inflectra (infliximab-dyyb), for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Top